AN2・セラピューティクス
AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.18 | $0 | -$7M |
| 2026 Q1 | -0.29 | $0 | -$12M |
| 2025 Q4 | -0.29 | $0 | -$5M |
| 2025 Q3 | -0.31 | $0 | -$6M |
| 2025 Q2 | -0.21 | $0 | -$8M |
| 2025 Q1 | -0.35 | $0 | -$11M |
| 2024 Q4 |
| -0.25 |
| $0 |
| -$5M |
| 2024 Q3 | -0.43 | $0 | -$12M |